Suggested benefit in PCV chemoradiotherapy for both IDH-mutant WHO-defined molecular subgroups
Analyses of NRG Oncology/RTOG 9802 Suggests both IDH-mutant WHO-defined molecular subgroups of high-risk low-grade gliomas may benefit from the addition...